AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 35455529
Drug: Occupational therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Occupational therapy via telerehabilitation (5 sessions per week, 1 hour each for 3 weeks)
Trial: 34872405
Drug: Sham treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment (n=21)
Trial: 32598752
Drug: rabeprazole 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 40 mg
Trial: 32598752
Drug: standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard dose rabeprazole
Trial: 32598752
Drug: IL‐1β CC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IL‐1β CC genotype
Trial: 33980690
Drug: Target LDL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target LDL cholesterol of <70 mg/dL
Trial: 34963300
Drug: Target LDL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Target LDL cholesterol of 100±10 mg/dL
Trial: 34623761
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of perioperative antibiotics (piperacillin + tazobactam - 4.5 g intravenous at fixed 8 hourly intervals)
Trial: 34623761
Drug: Nine doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nine doses of perioperative antibiotics (piperacillin + tazobactam - 4.5 g intravenous at fixed 8 hourly intervals)
Trial: 34623761
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of perioperative antibiotics
Trial: 34623761
Drug: Nine doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nine doses of perioperative antibiotics
Trial: 35577410
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy (CBT) for 4 months
Trial: 32870340
Drug: Vaginal hysterectomy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal hysterectomy with uterosacral ligament suspension
Trial: 32740291
Drug: 6.4% maltodextrin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6.4% maltodextrin (CHO) solution
Trial: 32740291
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (WAT, PLA, CHO)
Trial: 35748295
Drug: Corrected insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corrected insulin response (CIR)
Trial: 33141785
Drug: Dance/Movement Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dance/Movement Therapy (DMT)
Trial: 33141785
Drug: Verbal Treatment
RxNorm normalized name: HERBAL MISCELLANEOUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbal Treatment as Usual (TAU)
Trial: 35593501
Drug: Isoflavone supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone supplementation (single oral tablet of soy extract for 30 days)
Trial: 35593501
Drug: Estradiol treatment
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol treatment (0.5 μg subcutaneous injection in sesame oil for 30 days)
Trial: 35593501
Drug: Control (subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (subcutaneous injections of vehicle and oral placebo for 30 days)
Trial: 34418400
Drug: Tolebrutinib 5
RxNorm normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolebrutinib 5 mg
Trial: 34418400
Drug: Tolebrutinib 15
RxNorm normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolebrutinib 15 mg
Trial: 34418400
Drug: Tolebrutinib 30
RxNorm normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolebrutinib 30 mg
Trial: 34418400
Drug: Tolebrutinib 60
RxNorm normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolebrutinib 60 mg
Trial: 34724345
Drug: Tolebrutinib 120
RxNorm normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolebrutinib 120 mg
Trial: 34724345
Drug: Tolebrutinib 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolebrutinib 7.5 mg (multiple ascending dose)
Trial: 34724345
Drug: Tolebrutinib 15
RxNorm normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolebrutinib 15 mg (multiple ascending dose)
Trial: 34724345
Drug: Tolebrutinib 30
RxNorm normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolebrutinib 30 mg (multiple ascending dose)
Trial: 34724345
Drug: Tolebrutinib 60
RxNorm normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolebrutinib 60 mg (multiple ascending dose)
Trial: 34724345
Drug: Tolebrutinib 90
RxNorm normalized name: Tolebrutinib
DrugBank: Tolebrutinib (DB18715)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolebrutinib 90 mg (multiple ascending dose)
Trial: 33475318
Drug: Nomogram based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nomogram based on combination model
Trial: 32919897
Drug: Ultrasound-guided dextrose
RxNorm normalized name: Dextrose
DrugBank: Dextrose, unspecified form (DB09341)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided dextrose prolotherapy (2 cc dextrose 20% injection, 2 sessions)
Trial: 32919897
Drug: Radial extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radial extracorporeal shock wave therapy (ESWT, 3 sessions)
Trial: 35681620
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg QD)
Trial: 35681620
Drug: Pasireotide-LAR (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pasireotide-LAR (60 mg Q4 weeks)
Trial: 35681620
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Everolimus and Pasireotide-LAR
Trial: 33428870
Drug: 2 +
RxNorm normalized name: dHER2 + AS15 ASCI
DrugBank: SB719125 (DB16753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 + 1 schedule of the 13-valent pneumococcal conjugate vaccine (PCV13) with 4CMenB at 2, 4, and 12 months of age.
Trial: 33428870
Drug: 1 +
RxNorm normalized name: Prenatal Vitamins Oral Tablet [PRENAZYME 1 + 1]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 + 1 schedule of the 13-valent pneumococcal conjugate vaccine (PCV13) with 4CMenB at 3 and 12 months of age.
Trial: 34135111
Drug: Daily energy
RxNorm normalized name: CVS Daily Energy Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily energy restriction (75:75)
Trial: 35792962
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g amoxicillin administered 1 hour before surgery, followed by 1.5 g each for the first 3 postoperative days
Trial: 33534047
Drug: Methylprednisolone (MP)
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (MP) 40 mg bid for 3 days followed by 20 mg bid for 3 days
Trial: 32155883
Drug: DHA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA supplementation (1250 mg daily for 12 weeks)
Trial: 32394655
Drug: Omeprazole enteric
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole enteric capsules (OME), 20 mg twice a day for 8 weeks
Trial: 33062629
Drug: Both formulations
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both formulations (test and reference)
Trial: 33561214
Drug: SQ-LNS (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ-LNS (800 μg RE/20g) during pregnancy and the first 6 mo postpartum; children received SQ-LNS (400 μg RE/20 g) from 6 to 18 mo of age.
Trial: 33561214
Drug: Multiple micronutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrients (MMN; 800 μg retinol equivalent (RE)/capsule) during pregnancy only.
Trial: 33561214
Drug: SQ-LNS (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ-LNS (400 μg RE/20 g) for children from 6 to 18 mo of age.
Trial: 33561214
Drug: Multiple micronutrients
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple micronutrients (MMN) and Iron and folic acid (IFA) for children (no supplement).
Trial: 32613240
Drug: Physiologic E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic E2 (∼180 pg/ml) with P4 10 mg/day
Trial: 32613240
Drug: Moderately supraphysiologic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderately supraphysiologic E2 (600-800 pg/ml) with P4 10 mg/day
Trial: 32613240
Drug: Supraphysiologic E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supraphysiologic E2 (2000 pg/ml) with P4 10 mg/day
Trial: 33766497
Drug: BH4 treatment
RxNorm normalized name: 6R-BH4
DrugBank: Sapropterin (DB00360)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: BH4 treatment
Trial: 34708917
Drug: Pentazocine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (0.5 mg/kg)
Trial: 34214362
Drug: Centella asiatica
RxNorm normalized name: Centella asiatica
DrugBank: Centella asiatica (DB14256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centella asiatica cream applied twice a day
Trial: 34214362
Drug: Ceramide cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceramide cream applied twice a day
Trial: 33081849
Drug: Hydroxychloroquine 400
RxNorm normalized name: hydroxychloroquine 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 400 mg twice on first day followed by 400 mg daily for 10 days + Ribavirin (1.2 g loading dose followed by 600 mg every 12 hours for 10 days) + Standard Treatment (STNS)
Trial: 33081849
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment (STNS)
Trial: 33081849
Drug: Lopinavir (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir (200 mg) + Ritonavir (50 mg) two tablets twice daily + Ribavirin (1.2 g loading dose followed by 600 mg every 12 hours for 10 days) + Standard Treatment (STs)
Trial: 33081849
Drug: Hydroxychloroquine 400
RxNorm normalized name: hydroxychloroquine 400 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine 400 mg twice on first day followed by 400 mg daily for 10 days + Ribavirin (1.2 g loading dose followed by 600 mg every 12 hours for 10 days) + Standard Treatment (STs)
Trial: 33081849
Drug: Standard Treatment
RxNorm normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Standard Treatment (STs)
Trial: 32450838
Drug: Regular treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular treatment interval cohort (3 initial monthly IVT-AFL injections followed by regular injections every 2 months)
Trial: 32450838
Drug: Irregular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irregular treatment interval cohort with initial doses (3 initial monthly IVT-AFL injections)
Trial: 32450838
Drug: Irregular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irregular treatment interval cohort without initial doses
Trial: 33104981
Drug: Fluticasone furoate
RxNorm normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluticasone furoate nasal spray 55 μg
Trial: 33104981
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group without intranasal steroid
Trial: 33171964
Drug: Aspartame (0.425
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspartame (0.425 g, 14% of ADI)
Trial: 33171964
Drug: Sucralose (0.136
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralose (0.136 g, 20% of ADI)
Trial: 33835666
Drug: Immuno-oncology (IO)
RxNorm normalized name: Io-Shield
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immuno-oncology (IO) based systemic treatment
Trial: 32098739
Drug: Individually-tailored educational
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individually-tailored educational videos about maternal and infant vaccines and the cocooning strategy
Trial: 32098739
Drug: Intention to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intention to receive maternal influenza vaccine, perceived safety of maternal Tdap vaccine, perceived efficacy of maternal influenza vaccine, perceived susceptibility to and severity of influenza during pregnancy, trust in vaccine information from CDC and academic institutions
Trial: 32098739
Drug: Uncertainty about
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Uncertainty about infant vaccine intentions
Trial: 33650471
Drug: Antibiotics prescribed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotics prescribed (154 patients, 38.1%)
Trial: 33650471
Drug: No antibiotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antibiotics prescribed (250 patients, 61.9%)
Trial: 35830133
Drug: Nano-suspension of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nano-suspension of Talaromyces flavus at concentrations of 1, 4, and 5 per thousand (soil addition method)
Trial: 35830133
Drug: Registered formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Registered formulation of Talaromin (seed impregnation and soil addition methods)
Trial: 33082342
Drug: Hydroxychloroquine therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine therapy (400 mg twice daily for seven days)
Trial: 35662514
Drug: Neostigmine (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neostigmine (0.05 mg/kg) + Atropine (0.02 mg/kg)
Trial: 35153119
Drug: Sugammadex (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugammadex (1 mg/kg) after Neostigmine
Trial: 34600264
Drug: ondansetron 4
RxNorm normalized name: ondansetron 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 4 mg twice daily
Trial: 33685776
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) antimicrobials
Trial: 33685776
Drug: Oral (PO)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (PO) antimicrobials
Trial: 32645765
Drug: Nitric oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitric oxide administration
Trial: 35834633
Drug: BSRGE extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSRGE extract (30 mg of GABA per day)
Trial: 35961842
Drug: Reflexology treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reflexology treatment along with usual medical care
Trial: 32499757
Drug: Anastrozole (AI)
RxNorm normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anastrozole (AI) plus weight loss (WL) at 1 mg daily for 6 months
Trial: 35151367
Drug: Active hexose
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active hexose correlated compound (AHCC)
Trial: 34875139
Drug: QR678 Neo®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: QR678 Neo® hair growth factor formulation
Trial: 32677375
Drug: Peramivir 600
RxNorm normalized name: peramivir 600 mg in 60 mL INTRAVENOUS SOLUTION [Rapivab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peramivir 600 mg on two consecutive days (peramivir-repeat)
Trial: 32677375
Drug: Peramivir 300
RxNorm normalized name: Peramivir
DrugBank: Peramivir (DB06614)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Peramivir 300 mg single dose (peramivir-single)
Trial: 34857578
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy plus axillary treatment (ANC or axillary RT)
Trial: 34857578
Drug: Adjuvant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant therapy (standard care)
Trial: 32510754
Drug: N. sativa
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N. sativa oil (1,000 mg daily for 8 weeks)
Trial: 34928294
Drug: Daily low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily low-dose prednisolone (15 mg/m2 daily for 6 days)
Trial: 34928294
Drug: Daily low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daily low-dose prednisolone
Trial: 33927582
Drug: Cefuroxime axetil
RxNorm normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefuroxime axetil tablets (250 mg) - various brands
Trial: 32197931
Drug: Low-dose thoracic
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose thoracic CT scan
Trial: 32197931
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of smoking cessation and lung cancer screening
Trial: 36065795
Drug: Spironolactone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (up to 50 mg/day)
Trial: 36209245
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5 mg in 100 ml isotonic saline)
Trial: 36209245
Drug: Placebo (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (100 ml isotonic saline only)
Trial: 35436810
Drug: Subanesthetic dose
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subanesthetic dose of esketamine 0.125 mg·kg‐1·h‐1 (group ES1)
Trial: 35436810
Drug: Subanesthetic dose
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subanesthetic dose of esketamine 0.250 mg·kg‐1·h‐1 (group ES2)
Trial: 34262052
Drug: Intramuscular (IM)
RxNorm normalized name: intramuscular immunoglobulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular (IM) route
Trial: 35709811
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A virus vaccine (control)
Trial: 35016205
Drug: DAV132 (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAV132 (7.5 g, 3 times a day, orally)
Trial: 33794784
Drug: VSL#3® probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VSL#3® probiotic supplementation (2 sachets twice daily for 10 weeks)
Trial: 32989783
Drug: Hair Follicle
RxNorm normalized name: BIOTIN 2 g in 30 mL TOPICAL OIL [Reactivate Hair Follicles]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hair Follicle Cell Suspension (HFCS)
Trial: 32989783
Drug: Epidermal Cell
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidermal Cell Suspension (ECS)
Trial: 32391548
Drug: CEMA cutpoint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEMA cutpoint of 27 pmol/mL urine
Trial: 32391548
Drug: Different cotinine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Different cotinine cutpoints (10-30 ng/mL)
Trial: 33770484
Drug: Dexamethasone plus
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone plus oseltamivir (40 mg/day for 4 days + 75 mg twice a day for 10 days)
Trial: 32657903
Drug: Massage application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Massage application with ultrasound gel (placebo, n = 15)
Trial: 32390705
Drug: 1 L-PEG
RxNorm normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 L-PEG preparation (Plenvu®)
Trial: 32390705
Drug: 2 L-PEG
RxNorm normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 L-PEG preparation (Moviprep® or Clensia®)
Trial: 32390705
Drug: 4 L-PEG
RxNorm normalized name: Peg/L-asparaginase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 4 L-PEG preparation (Selgesse®)
Trial: 39710693
Drug: High-dose dexamethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose dexamethasone
Trial: 32015090
Drug: Intravenous rt-PA
RxNorm normalized name: rt-PA
DrugBank: Alteplase (DB00009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous rt-PA
Trial: 34313917
Drug: Diphenhydramine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diphenhydramine 0.4 mg/kg, acetaminophen 1g, ondansetron 4 mg
Trial: 32661108
Drug: Afrezza high
RxNorm normalized name: Afrezza
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Afrezza high dose (AH)
Trial: 32661108
Drug: Afrezza low
RxNorm normalized name: Afrezza
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Afrezza low dose (AL)
Trial: 32661108
Drug: Standard SC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard SC rapid-acting insulin (aspart)
Trial: 35718438
Drug: Zygomatic implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zygomatic implants
Trial: 616084148
Drug: Half-dose verteporfin
RxNorm normalized name: Verteporfin
DrugBank: Verteporfin (DB00460)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Half-dose verteporfin photodynamic therapy (hd-PDT)